Literature DB >> 24332102

Balancing curability and unnecessary surgery in the context of computed tomography screening for lung cancer.

Raja Flores1, Thomas Bauer2, Ralph Aye3, Shahriyour Andaz4, Leslie Kohman5, Barry Sheppard6, William Mayfield7, Richard Thurer8, Michael Smith9, Robert Korst10, Michaela Straznicka11, Fred Grannis12, Harvey Pass13, Cliff Connery1, Rowena Yip1, James P Smith14, David Yankelevitz1, Claudia Henschke15, Nasser Altorki16.   

Abstract

OBJECTIVE: Surgical management is a critical component of computed tomography (CT) screening for lung cancer. We report the results for US sites in a large ongoing screening program, the International Early Lung Cancer Action Program (I-ELCAP).
METHODS: We identified all patients who underwent surgical resection. We compared the results before (1993-2005) and after (2006-2011) termination of the National Lung Screening Trial to identify emerging trends.
RESULTS: Among 31,646 baseline and 37,861 annual repeat CT screenings, 492 patients underwent surgical resection; 437 (89%) were diagnosed with lung cancer; 396 (91%) had clinical stage I disease. In the 54 (11%) patients with nonmalignant disease, resection was sublobar in 48 and lobectomy in 6. The estimated cure rate based on the 15-year Kaplan-Meier survival for all 428 patients (excluding 9 typical carcinoids) with lung cancer was 84% (95% confidence interval [CI], 80%-88%) and 88% (95% CI, 83%-92%) for clinical stage I disease resected within 1 month of diagnosis. Video-assisted thoracoscopic surgery and sublobar resection increased significantly, from 10% to 34% (P < .0001) and 22% to 34% (P = .01) respectively; there were no significant differences in the percentage of malignant diagnoses (90% vs 87%, P = .36), clinical stage I (92% vs 89%, P = .33), pathologic stage I (85% vs 82%, P = .44), tumor size (P = .61), or cell type (P = .81).
CONCLUSIONS: The frequency and extent of surgery for nonmalignant disease can be minimized in a CT screening program and provide a high cure rate for those diagnosed with lung cancer and undergoing surgical resection.
Copyright © 2014 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24332102     DOI: 10.1016/j.jtcvs.2013.11.001

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  17 in total

1.  Recommendations from the European Society of Thoracic Surgeons (ESTS) regarding computed tomography screening for lung cancer in Europe.

Authors:  Jesper Holst Pedersen; Witold Rzyman; Giulia Veronesi; Thomas A D'Amico; Paul Van Schil; Laureano Molins; Gilbert Massard; Gaetano Rocco
Journal:  Eur J Cardiothorac Surg       Date:  2017-03-01       Impact factor: 4.191

2.  How to deal with subcentimeter lung cancer: a moving target!

Authors:  Paul E Van Schil
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

3.  Biopsy first: Lessons learned from Cancer and Leukemia Group B (CALGB) 140503.

Authors:  Leslie J Kohman; Lin Gu; Nasser Altorki; Ernest Scalzetti; Linda J Veit; Jason M Wallen; Xiaofei Wang
Journal:  J Thorac Cardiovasc Surg       Date:  2017-02-07       Impact factor: 5.209

4.  CT Screening for Lung Cancer: Nonsolid Nodules in Baseline and Annual Repeat Rounds.

Authors:  David F Yankelevitz; Rowena Yip; James P Smith; Mingzhu Liang; Ying Liu; Dong Ming Xu; Mary M Salvatore; Andrea S Wolf; Raja M Flores; Claudia I Henschke
Journal:  Radiology       Date:  2015-06-23       Impact factor: 11.105

5.  Five reasons for caution in advocating low-dose computerized tomographic lung cancer screening.

Authors:  Jerome M Reich; Jong S Kim
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

6.  Computed Tomography Screening for Lung Cancer: Mediastinal Lymph Node Resection in Stage IA Nonsmall Cell Lung Cancer Manifesting as Subsolid and Solid Nodules.

Authors:  Raja M Flores; Daniel Nicastri; Thomas Bauer; Ralph Aye; Shahriyour Andaz; Leslie Kohman; Barry Sheppard; William Mayfield; Richard Thurer; Robert Korst; Michaela Straznicka; Fred Grannis; Harvey Pass; Cliff Connery; Rowena Yip; James P Smith; David F Yankelevitz; Claudia I Henschke; Nasser K Altorki
Journal:  Ann Surg       Date:  2017-05       Impact factor: 12.969

Review 7.  The importance of the regimen of screening in maximizing the benefit and minimizing the harms.

Authors:  Claudia I Henschke; Kunwei Li; Rowena Yip; Mary Salvatore; David F Yankelevitz
Journal:  Ann Transl Med       Date:  2016-04

Review 8.  Update in Lung Cancer 2014.

Authors:  Avrum Spira; Balazs Halmos; Charles A Powell
Journal:  Am J Respir Crit Care Med       Date:  2015-08-01       Impact factor: 21.405

Review 9.  An update on CT screening for lung cancer: the first major targeted cancer screening programme.

Authors:  David R Baldwin; Matthew E J Callister
Journal:  Br J Radiol       Date:  2020-09-07       Impact factor: 3.039

10.  Virtual fluoroscopy during transbronchial biopsy for locating ground-glass nodules not visible on X-ray fluoroscopy.

Authors:  Toshiyuki Nakai; Takehiro Izumo; Yuji Matsumoto; Takaaki Tsuchida
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.